Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Needs Stronger Leadership For Biotech To Prosper

Executive Summary

As Australia ends a resources boom, a decline in manufacturing has left the country vulnerable, and a concerted investment in biotechnology could transform the country, according to a new report.

You may also be interested in...



Novartis adds novel pain program via $200m Spinifex buy

Executing on its planned strategy for an 'exit' exactly on schedule, Australian/US biotech Spinifex Pharmaceuticals has agreed to be acquired by Novartis for $200m plus undisclosed development and regulatory milestones.

Strides Completes Acquisition Of Endo US Facility And ANDAs

Two months after announcing the deal, Strides Pharma Science has closed its acquisition of a US manufacturing site and basket of ANDAs from Endo, doubling the company’s burgeoning US business and providing much-needed cash to the US-based company.

Sandoz Stung By The US Again As Sales And Margins Fall In Q3

As parent Novartis announced plans for a strategic review for its Sandoz business, the generics and biosimilars unit posted falling sales again for the third quarter of 2021, after championing stability in Q2. Sandoz is banking on biosimilars to return to growth.

Topics

Related Companies

UsernamePublicRestriction

Register

SC097667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel